| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
Symbicort Aerosphere is owned by Astrazeneca.
Symbicort Aerosphere contains Budesonide; Formoterol Fumarate.
Symbicort Aerosphere has a total of 2 drug patents out of which 0 drug patents have expired.
Symbicort Aerosphere was authorised for market use on 28 April, 2023.
Symbicort Aerosphere is available in aerosol, metered;inhalation dosage forms.
Symbicort Aerosphere can be used as maintenance treatment of patients with chronic obstructive pulmonary disease (copd).
The generics of Symbicort Aerosphere are possible to be released after 28 May, 2030.
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
SYMBICORT AEROSPHERE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic